FEATURED PRESS RELEASE
Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Gyroscope Therapeutics led consortium secures INNOVATE UK funding to develop a suspension platform for cost effective manufacture of novel AAV gene therapies
Gyroscope Therapeutics and Freeline Therapeutics are partnering with two research organisations, NHSBT’s Clinical Biotechnology Centre (CBC) and the Centre for Process Innovation (CPI), to develop and design a manufacturing platform to produce novel (adeno-associated virus) AAV gene therapies.
Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases such as age related macular degeneration (AMD), is pleased to announce the appointment of Dr Soraya Bekkali as Chief Executive Officer and Director of its Board.